ECSP066548A - 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica - Google Patents

4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica

Info

Publication number
ECSP066548A
ECSP066548A EC2006006548A ECSP066548A ECSP066548A EC SP066548 A ECSP066548 A EC SP066548A EC 2006006548 A EC2006006548 A EC 2006006548A EC SP066548 A ECSP066548 A EC SP066548A EC SP066548 A ECSP066548 A EC SP066548A
Authority
EC
Ecuador
Prior art keywords
treatment
ome
chronic
leukemia
quinolincarbonitrilos
Prior art date
Application number
EC2006006548A
Other languages
English (en)
Inventor
Frank Charles Boschelli
Kim Timothy Arndt
Jennifer Michele Golas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP066548A publication Critical patent/ECSP066548A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de la fórmula (I) en donde n es un entero de 1-3; X es N, CH, siempre que cuando X es N, n es 2 ó 3; R es alquilo de 1 a 3 átomos de carbono; R1 es 2,4-diCl, 5-OMe; 2,4-diCl; 3,4,5-tri-OMe; 3-Cl, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCl, 5-OEt; R2 es alquilo de 1 a 2 átomos de carbono y sales farmacéuticamente aceptables de los mismos son útiles para el tratamiento de leucemia mielógena crónica (CML).
EC2006006548A 2003-11-06 2006-05-05 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica ECSP066548A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06

Publications (1)

Publication Number Publication Date
ECSP066548A true ECSP066548A (es) 2006-10-17

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006548A ECSP066548A (es) 2003-11-06 2006-05-05 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica

Country Status (18)

Country Link
US (2) US7417148B2 (es)
EP (1) EP1680119A1 (es)
JP (1) JP2007533655A (es)
KR (1) KR20060118461A (es)
CN (1) CN1874776A (es)
AU (1) AU2004289243B2 (es)
BR (1) BRPI0416289A (es)
CA (1) CA2543163A1 (es)
CO (1) CO5690608A2 (es)
CR (1) CR8350A (es)
EC (1) ECSP066548A (es)
IL (1) IL175424A0 (es)
MX (1) MXPA06004744A (es)
NO (1) NO20062255L (es)
RU (1) RU2006113691A (es)
SG (1) SG146681A1 (es)
WO (1) WO2005046693A1 (es)
ZA (1) ZA200603596B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US7468379B2 (en) 2005-06-17 2008-12-23 The Board Of Regents Of The University Of Texas System Inhibition of osteolytic lesions by SRC kinase inhibitors
KR20080027275A (ko) * 2005-06-24 2008-03-26 와이어쓰 암의 치료를 위한 4-아닐리노-3-퀴놀린카르보니트릴
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
HUE055524T2 (hu) * 2007-06-01 2021-11-29 Wyeth Llc A bcrabl génben 1457T>C mutációt tartalmazó, imatinibbel szemben ellenálló krónikus mielogén leukémia kezelése bozutinib vegyület alkalmazásával
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はahi1の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
IN2014CH00840A (es) 2014-02-20 2015-09-18 Apotex Inc
CN107530430A (zh) 2015-01-13 2018-01-02 国立大学法人京都大学 用于预防和/或治疗肌萎缩性侧索硬化症的药剂
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
US12398355B2 (en) 2019-04-09 2025-08-26 Massachusetts Institute Of Technology Micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Also Published As

Publication number Publication date
SG146681A1 (en) 2008-10-30
US7919625B2 (en) 2011-04-05
JP2007533655A (ja) 2007-11-22
CN1874776A (zh) 2006-12-06
WO2005046693A1 (en) 2005-05-26
IL175424A0 (en) 2008-04-13
CO5690608A2 (es) 2006-10-31
US20100029677A1 (en) 2010-02-04
BRPI0416289A (pt) 2007-01-23
CR8350A (es) 2006-10-06
AU2004289243B2 (en) 2010-07-22
US7417148B2 (en) 2008-08-26
EP1680119A1 (en) 2006-07-19
ZA200603596B (en) 2009-12-30
MXPA06004744A (es) 2006-07-05
AU2004289243A1 (en) 2005-05-26
KR20060118461A (ko) 2006-11-23
NO20062255L (no) 2006-08-01
US20050101780A1 (en) 2005-05-12
CA2543163A1 (en) 2005-05-26
RU2006113691A (ru) 2007-12-20

Similar Documents

Publication Publication Date Title
ECSP066548A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica
UY27918A1 (es) Derivados de benzodioxol
ECSP056127A (es) Inhibidores de 3-quinasa de fosfatidil-inositol
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
AR041867A1 (es) Agente para prevenir o tratar neuropatia
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
AR048741A1 (es) Derivados de omega-carboxiaril difenil urea sustituida
ES2571779T3 (es) Inhibidores de cinasa a base de nicotinamida
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
UY26958A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
CY1107403T1 (el) Μια μεθοδος δια την παρασκευη υπερινδοπριλης,των αναλογων ενωσεων αυτης και των αλατων αυτων με χρησιμοποιηση ενδιαμεσων ενωσεων 2,5-διοξο-οξαζολιδινης
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
MXPA05007341A (es) Derivados de 2-piperidona como agonistas de prostaglandina.
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES
ECSP055972A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas
MY136824A (en) Substituted benzoxazinones and uses thereof
UY27979A1 (es) Indoles sustituidos en posición 2,4
TW200600971A (en) Calixresorcinarene compounds, photoresist base materials, and compositions thereof
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
AR041339A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
TW200722433A (en) Phosphorus compounds, use thereof and flame retarding polyester fibers
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
AR044175A1 (es) Compuestos de cefemo
AR057464A1 (es) Procedimiento para la preparacion de derivados de sulfonamida